Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 321

1.

Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Kim D, Ryba NL, Kalabalik J, Westrich L.

Drugs R D. 2018 Sep;18(3):167-189. doi: 10.1007/s40268-018-0246-8. Review.

2.

New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment.

Tellone V, Coppola P, Ammendola M, Di Loreto G, Picollo R, Del Vecchio A, Comandini A, Garofolo F, Tongiani S.

Drugs R D. 2018 Sep;18(3):237-245. doi: 10.1007/s40268-018-0245-9.

3.

Risks and Benefits of Sodium Polystyrene Sulfonate for Hyperkalemia in Patients on Maintenance Hemodialysis.

Nakamura T, Fujisaki T, Miyazono M, Yoshihara M, Jinnouchi H, Fukunari K, Awanami Y, Ikeda Y, Hashimoto K, Yamasaki M, Nonaka Y, Fukuda M, Kishi T, Ikeda Y.

Drugs R D. 2018 Sep;18(3):231-235. doi: 10.1007/s40268-018-0244-x.

4.

Correction to: Evaluation of Cardiovascular Disease Risk in HIV‑1-Infected Patients Treated with Darunavir.

Opsomer M, Dimitrova D, Verspeelt J, Purrington A, Mehbob A, Chavers S, Pai H, Vanveggel S, Luo D, Brown K, Moecklinghoff C, Nettles RE, Boven K.

Drugs R D. 2018 Sep;18(3):249-250. doi: 10.1007/s40268-018-0243-y.

5.

Comments on: "In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea".

Gil D.

Drugs R D. 2018 Sep;18(3):165-166. doi: 10.1007/s40268-018-0242-z. No abstract available.

6.

The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients.

Bray VJ, Broadwell A, Baraf HSB, Black S, Brady BL, Tkacz J, Yarngo L, DeHoratius RJ.

Drugs R D. 2018 Sep;18(3):211-219. doi: 10.1007/s40268-018-0240-1.

7.

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers.

Dimelow R, Wright JG, MacPherson M, Newell P, Das S.

Drugs R D. 2018 Sep;18(3):221-230. doi: 10.1007/s40268-018-0241-0.

8.

Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.

Opsomer M, Dimitrova D, Verspeelt J, Purrington A, Mehbob A, Chavers S, Pai H, Vanveggel S, Luo D, Brown K, Moecklinghoff C, Nettles RE, Boven K.

Drugs R D. 2018 Sep;18(3):199-210. doi: 10.1007/s40268-018-0238-8. Erratum in: Drugs R D. 2018 Aug 6;:.

9.

Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, Coma J, Ferreras J, Moya J, Tomás A, Estivill P, Rodelas F, Jiménez AJ, Sanz A.

Drugs R D. 2018 Jul 9. doi: 10.1007/s40268-018-0239-7. [Epub ahead of print]

10.

Octreotide Use in Neonates: A Case Series.

Zaki SA, Krishnamurthy MB, Malhotra A.

Drugs R D. 2018 Sep;18(3):191-198. doi: 10.1007/s40268-018-0237-9.

11.

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wählby Hamrén U, Wray H.

Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x.

12.

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R.

Drugs R D. 2018 Jun;18(2):163. doi: 10.1007/s40268-018-0234-z.

13.

Co-crystal of Tramadol-Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial.

López-Cedrún J, Videla S, Burgueño M, Juárez I, Aboul-Hosn S, Martín-Granizo R, Grau J, Puche M, Gil-Diez JL, Hueto JA, Vaqué A, Sust M, Plata-Salamán C, Monner A; Co-Crystal of Tramadol-Celecoxib Team.

Drugs R D. 2018 Jun;18(2):137-148. doi: 10.1007/s40268-018-0235-y.

14.

Correction to: The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Auffret M, Drapier S, Vérin M.

Drugs R D. 2018 Jun;18(2):161. doi: 10.1007/s40268-018-0233-0.

15.
16.

Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication.

Guitart J, Vargas MI, De Sanctis V, Folch J, Salazar R, Fuentes J, Coma J, Ferreras J, Moya J, Tomás A, Estivill P, Rodelas F, Jiménez AJ, Sanz A.

Drugs R D. 2018 Jun;18(2):119-128. doi: 10.1007/s40268-018-0231-2. Erratum in: Drugs R D. 2018 Jul 9;:.

17.

The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Auffret M, Drapier S, Vérin M.

Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3. Review. Erratum in: Drugs R D. 2018 May 8;:.

18.

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment.

Marcinak J, Vakilynejad M, Kogame A, Tagawa Y.

Drugs R D. 2018 Jun;18(2):109-118. doi: 10.1007/s40268-018-0229-9.

19.

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes.

Liebl A, Mohan V, Yang W, Strojek K, Linjawi S.

Drugs R D. 2018 Mar;18(1):27-39. doi: 10.1007/s40268-018-0228-x. Review.

Supplemental Content

Loading ...
Support Center